Novel Technologies for Generation of Bispecific Constructs

Bispecific molecules can be differentiated from traditional monoclonal antibodies as they are able to address multiple targets simultaneously. These modalities may offer additional advantages with respect to target engagement that may not be feasible by traditional combination therapies with single agents. Therefore, design of bispecific constructs requires particular attention to target and drug selection for successful application of this class of therapeutics. In the past, progress in advancing bispecific molecules into the clinical arena was slow, mainly due to challenges associated with generating bispecific molecules in sufficient quality and quantity. However, due to recent progress in rapidly evolving technologies that encompass state-of-the-art engineering, production, and development of recombinant protein scaffolds, development of novel bispecific modalities has witnessed an exponential growth. In this chapter the current landscape for bi- and multi-specific modalities from design, production, and developability aspects is discussed.